1. Medtech Insight
  3. >>Cardiology

Market Intel: Emerging Markets Are Fertile Frontier For CRM Device-Makers

 
• By Nick Talamantes

The global cardiac rhythm management market is set to grow at a compound annual growth rate of 4.8% to about $13.5bn by 2021. This article, based on findings from a Meddevicetracker report, provides an in-depth look at where the growth markets are, the evolving competitive landscape, and discusses the key players and upcoming technological trends that will bolster this market.

Chest pain
The cardiac rhythm management device market is expected to keep growing, with fastest growth in emerging markets • Source: shutterstock.com

The global market for implantable cardiac rhythm management devices, which counts medtech heavyweights such as Medtronic, Boston Scientific, Biotronik – and now Abbott – among its key players, is anticipated to expand from an estimated $10.2bn in 2015 to roughly $13.5bn in total product sales by the year 2021, according to a new Meddevicetracker report.

The two major drivers for the surge in CRM products are the rising aging population at risk for developing cardiac rhythm disorders and an overall increase in heart disease, stated...

More from Cardiology

More from Device Area

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.